Evidence map›Paper›PMID 28220126›Full record

ArticleFrontiers in immunology2017

The Immunoregulatory Potential of Particle Radiation in Cancer Therapy.

Daniel K Ebner, Walter Tinganelli, Alexander Helm, Alessandra Bisio, Shigeru Yamada, Tadashi Kamada, Takashi Shimokawa, Marco Durante

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Emerging evidence for adapting radiotherapy to immunotherapy.Nature reviews. Clinical oncology · 2023
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Roadmap: proton therapy physics and biology.Physics in medicine and biology · 2021
    Review
  15. Review
  16. Tumor Hypoxia and Circulating Tumor Cells.International journal of molecular sciences · 2020
    Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Daniel K EbnerHospital of the National Institute of Radiological Sciences, National Institutes of Quantum and Radiological Science and Technology, Chiba, Japan; Brown University Alpert Medical School, Providence, RI, USA.
Walter TinganelliTrento Institute for Fundamental Physics and Applications-National Institute for Nuclear Physics (TIFPA-INFN), University of Trento , Trentino , Italy.
Alexander HelmTrento Institute for Fundamental Physics and Applications-National Institute for Nuclear Physics (TIFPA-INFN), University of Trento , Trentino , Italy.
Alessandra BisioCenter for Integrative Biology CIBIO, University of Trento , Povo, Trentino , Italy.
Shigeru YamadaHospital of the National Institute of Radiological Sciences, National Institutes of Quantum and Radiological Science and Technology , Chiba , Japan.
Tadashi KamadaHospital of the National Institute of Radiological Sciences, National Institutes of Quantum and Radiological Science and Technology , Chiba , Japan.
Takashi ShimokawaNational Institute of Radiological Sciences, National Institutes of Quantum and Radiological Science and Technology , Chiba , Japan.
Marco DuranteTrento Institute for Fundamental Physics and Applications-National Institute for Nuclear Physics (TIFPA-INFN), University of Trento, Trentino, Italy; Department of Physics, University Federico II, Naples, Italy.
National Institutes for Quantum and Radiological Science and Technology · JPIstituto Nazionale di Fisica Nucleare · ITUniversity of Trento · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer treatment, today, consists of surgery, chemotherapy, radiation, and most recently immunotherapy. Combination immunotherapy-radiotherapy (CIR) has experienced a surge in public attention due to numerous clinical publications outlining the reduction or elimination of metastatic disease, following treatment with specifically ipilimumab and radiotherapy. The mechanism behind CIR, however, remains unclear, though it is hypothesized that radiation transforms the tumor into an

Indexed as

abscopalcarbonimmunotherapyparticle therapyproton

Identifiers

PMID28220126
PMCPMC5292767
OpenAlexW2600890001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.